AIM: @entity11013 ( @entity11013 ) have been proven effective in controlling postnasal drip, decreasing inflammatory response, reducing nasal swelling, and increasing aeration of the sinuses such that @entity11013 are recommended as treatment of @entity1244 . METHODS: Fifty @entity1 with acute rhinosinusitis, 50 @entity1 with acute rhiniosinusitis and @entity2023 ( @entity2023 ), and 20 rhiniosinusitis @entity1 as control were selected for investigation. Each group had a single-blind treatment of three types: with coamoxiclav only, with coamoxiclav plus @entity11013 , and with matched placebo (without antibiotics and @entity11013 ) for two weeks. Nasal symptoms were then evaluated. The outcome was measured by using major symptom score (MSS) after treatment for 14 days. RESULTS: Therapeutic effectiveness was 92% in rhinosinusitis @entity1 treated with co-amoxiclav and 84% in those treated with co-amoxiclav plus @entity11013 . Among @entity1 with @entity1244 combined with @entity2023 , therapeutic efficacy was 88% for those treated with co-amoxiclav and 96% for those treated with co-amoxiclav plus @entity11013 . Only 30% of the symptoms were reduced in the placebo group. CONCLUSION: There are no statistical differences in the acute @entity1244 group treated with co-amoxiclav with or without @entity11013 . In the @entity1244 with @entity2023 group, the efficacy of co-amoxiclav with @entity11013 is higher than in @entity1 treated with co-amoxiclav alone.

Comparison of amoxicillin + clavulanate with or without intranasal fluticasone for the treatment of uncomplicated acute rhinosinusitis in XXXX .

@entity1244 :: ('MESH:D012852', 'Disease') :: ['sinusitis'] @entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['AR', 'allergic rhinitis'] @entity11013 :: ('MESH:C565152', 'Disease') :: ['Intranasal corticosteroids', 'INS']
@entity1 :: (9606,Species) :: ['children']
